Literature DB >> 2454373

Vasodilatory effects of carvedilol and pindolol.

S Sundberg1, K Tiihonen, A Gordin.   

Abstract

The effects of three different nonselective beta-blockers on central and peripheral hemodynamics as well as on pulmonary function were compared in 13 healthy subjects (19-37 years). The subjects were given carvedilol 50 mg, pindolol 10 mg, propranolol 80 mg, and placebo orally twice daily for 1 week in a double-blind, crossover, randomized manner. Heart rate, blood pressure, arterial calf blood flow (venous occlusion strain gauge plethysmography), and pulmonary function (flow-volume spirometry) were measured at the first and at the last trial day. Heart rate and blood pressure were lower on carvedilol and propranolol than on pindolol and placebo; the maximal bradycardiac effect was 13 and 17 beats/min and hypotensive effect 9/10 mm Hg and 10/7 mm Hg on carvedilol and propranolol, respectively. Both carvedilol and pindolol increased arterial flow by about 40% (p less than 0.05 and p less than 0.01, respectively) and reduced peripheral resistance by about 34% (p less than 0.05 and p less than 0.01, respectively), the effect persisting after 1 week of treatment. None of the medications had any noteworthy effects on pulmonary function. Two subjects complained of tremor on pindolol. We conclude that carvedilol and pindolol possess distinct vasodilatory properties. Carvedilol had a stronger hypotensive effect than pindolol and was well tolerated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2454373

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study.

Authors:  J J McPhillips; G T Schwemer; D I Scott; M Zinny; D Patterson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 3.  Pharmacology of antihypertensive agents with multiple actions.

Authors:  P A van Zwieten
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

5.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

Review 6.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

7.  Single and repeated doses of the vasodilator/beta-adrenergic antagonist, carvedilol, block cirazoline- and isoproterenol-mediated hemodynamic responses in the conscious rat.

Authors:  E F Smith; M J Slivjak; R Gagnon
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

8.  Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension.

Authors:  Y Nagakawa; Y Akedo; S Kaku; H Orimo
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 9.  The pharmacology of carvedilol.

Authors:  R R Ruffolo; M Gellai; J P Hieble; R N Willette; A J Nichols
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 10.  Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.

Authors:  William H Frishman; Linda S Henderson; Mary Ann Lukas
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.